| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer, EVP | Chief Financial Officer
2 companies
Julia Aijun Wang is Chief Financial Officer, EVP at LH, with reported holdings spanning 2 companies. Julia Aijun Wang's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $643K at current prices.
Our model assigns Julia Aijun Wang a middling insider score of 54/100, based on 11 past trades. Over a 12-month horizon, 45.5% of those trades were profitable, with an average 12-month return of -16.8%.
Julia Aijun Wang's largest disclosed position is in LH as Chief Financial Officer, EVP, worth about $643K.
Julia Aijun Wang has 20 Form 4 filings on record from July 2021 to February 2026, across 2 companies: Chief Financial Officer, EVP at Labcorp (LH), 2024–2026; Chief Financial Officer at BeOne Medicines (ONC), 2021–2024.
The 33 reported transactions were 14 open-market sales, 9 option or other derivative awards, 4 stock awards and 3 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 11 sales worth about $953K.
The largest open-market sale was 840 shares of ONC at an average $182.85 on June 23, 2023, about $154K. Twelve months later ONC was down 13%.
None of the 7 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2024 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 472 | $143.90 | $67,918.68 | -100% | +55.0% | +69.2% | |
| Jun 24, 2024 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 899 | $155.66 | $139,938.34 | -100% | +26.5% | +67.6% | |
| Jun 17, 2024 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 916 | $159.04 | $145,677.54 | -100% | +23.3% | +59.4% | |
| Feb 29, 2024 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 397 | $167.08 | $66,330.76 | -100% | -8.7% | +64.1% | |
| Jul 3, 2023 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 472 | $179.55 | $84,747.36 | -100% | -1.3% | -20.4% | |
| Jun 23, 2023 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 840 | $182.85 | $153,594.00 | -100% | +4.7% | -12.9% | |
| Jun 20, 2023 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 190 | $192.54 | $36,583.00 | -100% | +9.1% | -18.8% | |
| Mar 1, 2023 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 343 | $240.21 | $82,391.89 | -100% | -3.2% | -29.8% | |
| Jul 1, 2022 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 295 | $158.50 | $46,757.50 | -100% | -18.4% | +6.8% | |
| Jun 17, 2022 | ONC Beone Medicines Ltd. | Chief Financial Officer | Sell | 161 | $136.64 | $21,998.93 | -100% | +21.6% | +51.5% |